1 Children and adults with mild COVID-19 symptoms develop memory T cell immunity to SARS-CoV-2

2 Patricia Kaaijk^{1*}, Verónica Olivo Pimentel¹, Maarten E. Emmelot¹, Martien Poelen¹, Alper Cevirgel¹, Rutger M. Schepp¹,
3 Gerco den Hartog¹, Daphne F.M. Reukers¹, Lisa Beckers¹, Josine van Beek¹, Cécile A.C.M. van Els^{1,2}, Adam Meijer¹, Nynke
4 Y. Rots¹, Jelle de Wit¹

5 ¹ Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The
6 Netherlands. ² Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

7 *Corresponding author. Email: patricia.kaaijk@rivm.nl

8 Abstract

9 **Background:** Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to considerable
10 morbidity/mortality worldwide, but most infections, especially among children, have a mild course. However,
11 it remains largely unknown whether infected children develop cellular immune memory.

12 **Methods:** To determine whether a memory T cell response is being developed as an indicator for long-term
13 immune protection, we performed a longitudinal assessment of the SARS-CoV-2-specific T cell response by
14 IFN- γ ELISPOT and activation marker expression analyses of peripheral blood samples from children and adults
15 with mild-to-moderate COVID-19.

16 **Results:** Upon stimulation of PBMCs with heat-inactivated SARS-CoV-2 or overlapping peptides of spike (S-
17 SARS-CoV-2) and nucleocapsid proteins, we found S-SARS-CoV-2-specific IFN- γ T cell responses in most
18 infected children (83%) and all adults (100%) that were absent in unexposed controls. Frequencies of SARS-
19 CoV-2-specific T cells were higher in infected adults, especially in those with moderate symptoms, compared
20 to infected children. The S-SARS-CoV-2 IFN- γ T cell response correlated with S1-SARS-CoV-2-specific serum
21 IgM, IgG, and IgA antibody concentrations. Predominantly, effector memory CD4⁺ T cells of a Th1 phenotype
22 were activated upon exposure to SARS-CoV-2 antigens, which persisted for 4-8 weeks after symptom onset.
23 We detected very low frequencies of SARS-CoV-2-reactive CD8⁺ T cells in these individuals.

24 **Conclusions:** Our data indicate that an antigen-specific memory CD4⁺ T cell response is induced in children
25 and adults with mild SARS-CoV-2 infection. T cell immunity induced after mild COVID-19 could contribute to
26 protection against re-infection.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Keywords:** SARS-CoV-2; COVID-19; Mild symptoms; Children; T cell immunity

29 Introduction

30 Tremendous research efforts have advanced our understanding of immunity to SARS-CoV-2. Most data on the
 31 immune response to SARS-CoV-2 was obtained from severe COVID-19 cases [1-4]. However, the vast majority
 32 of infected individuals experience mild symptoms that do not require hospitalization [5-8]. The question
 33 remains whether individuals, including children, with an asymptomatic or mild SARS-CoV-2 infection, develop
 34 immune memory which may protect against subsequent SARS-CoV-2 infections. Persons with mild or
 35 asymptomatic infections often develop an antibody response, although not all cases do [8]. It has been shown
 36 that SARS-CoV-2-induced antibody levels are waning over time [6, 9-11]. On the other hand, T cell immunity is
 37 predicted to persist longer; after SARS-CoV infection in 2003, it was shown that T cell responses can persist for
 38 up to 17 years [12]. Some studies investigated the T cell immunity induced after SARS-CoV-2 infection in mild
 39 symptomatic adult cases [6, 8, 13-16], showing weaker T cell responses in mild than in moderate or severe
 40 COVID-19 cases. CD4⁺ T cell responses against SARS-CoV-2 were more prominent than the CD8⁺ T cell response
 41 in adults with mild-to-moderate infection [8, 15, 16], while qualitatively impaired CD4⁺ T cell responses have
 42 been reported for critically ill patients [15].
 43 Nevertheless, it remains unclear whether SARS-CoV-2 infection in children, usually showing a mild course,
 44 induces substantial T cell immunity. Only a few reports describe the immune responses in children with mild
 45 disease or asymptomatic infection, although in these studies T cells specifically reactive to SARS-CoV-2 were
 46 not investigated [17-19]. Recently, a study was published investigating SARS-CoV-2 specific T cell responses in
 47 children [20]. Induction of a sustainable T cell response is needed to provide immune memory for long-term
 48 protection against re-infections by facilitating an efficient and quick response upon re-exposure. Therefore,
 49 knowledge on the induction of memory T cell immunity after a mild course of SARS-CoV-2 infection in children
 50 and adults is useful for the consideration of the community mitigation measures needed to protect against
 51 COVID-19 and limit the spread of the virus.
 52 In the present study, we examined the frequency and the phenotypic/functional characteristics of SARS-CoV-2-
 53 reactive T cells in infected children and adults with mild to moderate symptoms. In addition, T cell responses
 54 correlated with SARS-CoV-2-specific serum IgM, IgG, and IgA antibody concentrations.

55 **Methods**

56 **Clinical studies**

57 In this prospective cohort study, described previously [21], households were enrolled in which one adult (index
58 case) tested PCR positive for SARS-CoV-2 between March-May, 2020. Blood samples were collected
59 longitudinally from SARS-CoV-2-infected children and adults of these households. Additionally, blood samples
60 from age-matched unexposed children (n=13) and adults (n=12) were collected from two other cohort studies
61 before the corona pandemic (respectively, 2018-2019 and 2009-2011). The protocol for the SARS-CoV-2-
62 related study, based on the WHO First Few Hundred protocol, was approved by the Medical-Ethical Review
63 Committee of University Medical Center Utrecht (NL13529.041.06). Protocols for the cohort studies with
64 unexposed children (Immfact, NL4679.094.13) and adults (NVI-255, NL29241.000.09) [22] were approved by
65 Medical-Ethical Review Committees of the Netherlands. Written informed consent was received from all
66 participants and/or from parents/guardians of minor participants (<16 years old). All trial-related activities
67 were conducted according to Good Clinical Practice, including the provisions of the Declaration of Helsinki.

69 **Interferon gamma ELISPOT**

70 Multiscreen filtration ELISPOT plates (Millipore, Merck) were prewetted with 35% ethanol for ≤ 1 minute and
71 washed with sterile water and PBS. Plates were coated with 5 $\mu\text{g}/\text{mL}$ anti-human IFN- γ antibodies (1-D1K,
72 Mabtech) overnight (4°C), then washed with PBS. PBMCs were incubated with heat-inactivated SARS-CoV-2
73 (MOI-3), or 15-mers overlapping peptides (11 amino acids overlap) covering whole spike protein of SARS-CoV-
74 2 (S-SARS-CoV-2), whole nucleocapsid protein (N-SARS-CoV-2), or S-HCoV-OC43 (0.1 $\mu\text{M}/\text{peptide}$, all JPT),
75 seeded on ELISPOT plates ($2 \cdot 10^5$ cells/well), and incubated for 20 hours, 37°C, 5% CO₂ in 100 μl AIM-V (Lonza)
76 with 2% human serum (Sigma). DMSO and PHA (Sigma) were negative and positive controls, respectively.
77 Subsequently, plates were washed and incubated for 1 hour with 1 $\mu\text{g}/\text{mL}$ anti-human IFN- γ detection
78 biotinylated-antibody (7-B6-1, Mabtech) in PBS-0.05% casein (Sigma). Plates were washed and incubated with
79 Streptavidin-poly-HRP (Sanquin) in PBS-0.05% casein for 1 hour. After washing, plates were developed with
80 TMB substrate (Mabtech). Spots were analyzed with CTL software. The number of spots from negative controls

was subtracted from total spot numbers induced by antigen-specific stimulation; more than 5 spots, after background subtraction, was considered positive. Supernatants and cells from ELISPOT plates were harvested for cytokine release assay and analysis of activation marker expression by T cells, respectively (described in Supplemental Methods).

Antibody assays

IgM, IgG, and IgA concentrations against SARS-CoV-2 monomeric spike-S1 (40591-V08H; Sino Biological) were determined in serum using a fluorescent bead-based immune assay as published previously [23], with previously determined cutoff values for seroprevalence [10].

Statistics

Statistical analyses were performed using Prism V7.0 (GraphPad). For unpaired comparisons, Mann-Whitney U test (two groups) or Kruskal-Wallis rank-sum test with Dunn's posthoc test (≥ 3 groups) were used. Paired data were compared using the Wilcoxon signed-rank test (two groups) or the Friedman test with Dunn's multiple comparison test (≥ 3 groups). Median values for paired comparisons were calculated from subjects with complete data for all time points. Correlation coefficients (r_s) were determined with Spearman's rank correlation. Non-parametric tests were used since data were mostly non-normally distributed according to the Shapiro-Wilk test. P values < 0.05 were considered significant.

99 Results

100 Study subjects

101 SARS-CoV-2 specific T cell responses were assessed from SARS-CoV-2-infected children and adults, and for
102 comparison from unexposed children and adults. Demographic and clinical characteristics are presented in
103 Table 1. Blood samples from 24 children and 27 adults with PCR-confirmed SARS-CoV-2 infection were
104 collected. The median time point of the first sample (T1) was for adults 12.5 days [interquartile range (IQR) 11-
105 14 days] and children 8 days [5.0-16 days] post-symptom onset. Additional blood samples were taken 10-14
106 days after T1 (referred to as 'T2') and only for adults also at 4-6 weeks after T1 (referred to as 'T3'). No
107 significant differences in major immune cell types were found over time after infection neither in children nor
108 adults, i.e. frequencies of total T cells, B cells, monocytes, or NK cells were comparable between infected
109 groups and healthy age-matched unexposed groups (Supplementary Figure 1).

111 SARS-CoV-2 specific IFN- γ ⁺ T cell response

112 IFN- γ ⁺-producing cells were detected by ELISPOT upon stimulation with overlapping peptides covering spike
113 protein (S) of SARS-CoV-2 (S-SARS-CoV-2) in 83% (20/24) of infected children and in 100% (27/27) of infected
114 adults, whereas IFN γ ⁺ responses were found in 0% (0/6) and 8.3% (1/12) of the unexposed children and adults,
115 respectively. Frequencies of SARS-CoV-2-specific IFN- γ ⁺ T cells were lower in infected children than in infected
116 adults (Figure 1A-C); the median spot forming units (SFU)/2.10⁵ PBMCs for infected children vs infected adults
117 was 18 vs 62 (P=0.0021) at T1 upon stimulation with S-SARS-CoV-2 (Figure 1A). At T1, a 2- to 6-fold higher
118 frequency of SARS-CoV-2-specific IFN- γ ⁺ T cells was found, depending on the antigenic stimulus used, in adults
119 with moderate symptoms compared to mild symptomatic adults (upon S-SARS-CoV-2-specific stimulation, 105
120 vs 45 SFU/2.10⁵ PBMCs at T1 (P=0.045) (Figure 1F-G)). At later time points, higher frequencies of IFN- γ -
121 producing T cells in moderately ill patients compared to mild symptomatic adults were only observed after
122 stimulation with overlapping peptides covering nucleocapsid protein (N) of SARS-CoV-2 (N-SARS-CoV-2) at T3
123 or with inactivated whole SARS-CoV-2 at T2 and T3. The higher frequencies of SARS-CoV-2-specific IFN- γ ⁺ T
124 cells observed in infected adults compared to children were mainly caused by the higher responses found in

adults with moderate symptoms. Nevertheless, the IFN- γ response of mild symptomatic adults also tended to be slightly higher than infected children (Figure 1E-F). The pre-existing T cell response against S-HCoV-OC43 of infected children was very low, although S-HCoV-OC43-specific T cell frequency was slightly higher at T2 compared to the age-matched unexposed control group (9.0 vs 1.0 SFU/ 2.10^5 PBMCs; $P=0.037$) (Figure 1D, left panel). In infected adults, no difference in numbers of S-HCoV-OC43-specific T cells was found between SARS-CoV-2-infected and unexposed adults (Figure 1D, right panel). In both SARS-CoV-2-infected children and adults, the frequency of IFN- γ^+ T cells was 4 to 60-fold lower after stimulation with S-HCoV-OC43 (Figure 1D) compared to stimulation with any of the SARS-CoV-2 antigens (Figure 1A-C). No significant difference in frequency of S-HCoV-OC43-reactive T cells was observed between unexposed adults and unexposed children or between mild and moderate COVID-19 cases.

Activation of effector memory CD4 $^+$ T cells upon SARS-CoV-2-specific stimulation

Especially the CD25 (IL-2R α) and CD137 (4-1BB) expression on T cells of infected subjects increased significantly upon the various SARS-CoV-2 antigenic stimulations compared to mock stimulation (Supplementary Figure 2). Primarily CD4 $^+$ T cells and not CD8 $^+$ T cells expressed CD25/CD137 activation markers upon SARS-CoV-2 antigenic stimulation, in infected subjects (Figure 2A-G, Supplementary Figure 3). Compared to the unexposed age-matched groups, higher frequencies of activated CD4 $^+$ T cells were observed in both infected children and infected adults after stimulation with any of the three SARS-CoV-2 antigen preparations. Frequencies of SARS-CoV-2-specific activated CD4 $^+$ T cells were significantly lower in infected children than in adults (upon S-SARS-CoV-2-specific stimulation, 0.04% CD25 $^+$ /CD137 $^+$ T cells of total CD4 $^+$ T cells for infected children vs 0.21% for infected adults at T1; $P=0.0035$) (Figure 2A-G). Frequencies of SARS-CoV-2-specific activated CD4 $^+$ T cells, irrespective of used SARS-CoV-2 antigen, were higher in the adults with moderate COVID-19 illness compared to adults with mild symptoms at T1. This difference was not observed at later time points (Figure 2A-G). The SARS-CoV-2-specific activated CD4 $^+$ T cells were mainly effector memory (CD45RO $^+$ /CCR7 $^-$) (T_{EM}) (Figure 2H).

151 *Correlations between SARS-CoV-2-specific IFN- γ ⁺ T cell responses and CD4⁺ T cell response*

152 In children, moderate correlations were observed between IFN- γ ⁺ T cell frequency and activated
153 (CD137⁺/CD25⁺)CD4⁺ T cells after stimulation with both S-SARS-CoV-2 ($r_s=0.45$; $P=0.036$) and N-SARS-CoV-2
154 ($r_s=0.64$; $P=0.004$) at T2, and at T1 only after stimulation with inactivated SARS-CoV-2 ($r_s=0.51$; $P=0.012$)
155 (Figure 3A). In adults, IFN- γ ⁺ T cell frequency and activated (CD137⁺/CD25⁺)CD4⁺ T cells correlated after
156 stimulation with both S-SARS-CoV-2 and N-SARS-CoV-2 at all three time points after infection (r_s ranging
157 between 0.43-0.66) and after stimulation with inactivated SARS-CoV-2 at T1 and T2 (respectively, $r_s=0.66$ and
158 $r_s=0.53$) (Figure 3B).

159

160 *SARS-CoV-2-specific release of cytokines*

161 Upon stimulation with S-SARS-CoV-2, PBMCs from SARS-CoV-2-infected children secreted more IL-2 than
162 unexposed children, albeit at very low amounts (3.7 vs 0.1 pg/ml; $P=0.030$), as well as IL-10 (1.5 vs 0.1 pg/ml;
163 $P=0.019$). Similar trends were observed in SARS-CoV-2-infected adults compared to unexposed adults, for
164 both IL-2 (18.0 vs 0.1 pg/ml; $P=0.0003$) and IL-10 (2.6 vs 0.1 pg/ml; $P=0.0087$) secretion. S-SARS-CoV-2-specific
165 IL-2 secretion was higher in infected adults compared to infected children ($P=0.015$). However, IL-2 secretion
166 was only significantly higher in adults with moderate COVID-19 (51.8 vs 3.7 pg/ml; $P=0.0026$) and not in adults
167 with mild symptoms compared to infected children (Figure 4). Other cytokines were only secreted at low levels
168 and not significantly.

169

170 *Correlations between SARS-CoV-2-specific IFN- γ ⁺ T cell frequency and antibody response*

171 Serum antibody concentrations against the SARS-CoV-2 Spike S1 protein (S1-SARS-CoV-2) above the previously
172 established cutoff level [10] at any of the two sampling time points were found in 83.3% (IgM), 79.2% (IgG),
173 and 75.0% (IgA) of the infected children. From the four children without detectable S-SARS-CoV-2-specific T
174 cell responses, two did have S1-SARS-CoV-2-specific IgM, IgG, and IgA antibodies; the other two did not. In
175 adults, 100%, 96.3%, and 88.9% were seropositive for respectively, IgM, IgG, and IgA antibodies to S1-SARS-
176 CoV-2 at any of the sampling time points. Interestingly, in children good correlations were observed between

177 S-SARS-CoV-2 IFN- γ ⁺ T cell frequency and S1-SARS-CoV-2-specific serum IgM, IgG and IgA concentrations,
 178 though this was only observed at T1 (for IgM, $R_s=0.73$ ($P<0.0001$); IgG, $r_s=0.74$ ($P<0.0001$); IgA, $r_s=0.66$
 179 ($P=0.0005$)) (Figure 5A). In adults, frequency of S-SARS-CoV-2-specific T cells was also correlated with S1-SARS-
 180 CoV-2-specific serum IgM concentrations at T2 and T3 (respectively, $r_s=0.42$ ($P=0.03$) and $r_s=0.49$ ($P=0.009$)),
 181 with S1-SARS-CoV-2-specific serum IgG concentrations at T2 and T3 (for both time points, $r_s=0.47$ ($P=0.01$)),
 182 and with S1-SARS-CoV-2-specific serum IgA concentrations at T3 ($r_s=0.44$ ($P=0.02$)) (Figure 5B).

183 Discussion

184 Most infections with SARS-CoV-2, especially among children, have a mild course. But, do children, despite
185 experiencing mild infection, develop memory T cell immunity? Here, we describe the kinetics, function, and
186 phenotype of SARS-CoV-2-specific T cells of infected children in comparison with adults experiencing mild to
187 moderate COVID-19 symptoms. Only limited studies have been reported investigating the immune responses
188 in children with mild/asymptomatic SARS-CoV-2 infection [17-20]. The strength of our study is that we
189 evaluated the recall T cell response upon SARS-CoV-2 specific stimulation, and compared it to unexposed
190 children and adults.

191 We found higher frequencies of SARS-CoV-2-specific IFN- γ ⁺ T cells in all infected groups compared to the
192 unexposed control groups after any of the three antigenic stimulations that included heat-inactivated SARS-
193 CoV-2, and overlapping peptides of SARS-CoV-2 spike protein (S-SARS-CoV-2), and nucleocapsid protein (N-
194 SARS-CoV-2). In general, frequencies of IFN- γ ⁺-T cells reactive against SARS-CoV-2 antigens were lower in
195 infected children, who generally had mild/asymptomatic infection, compared to infected adults. The lower
196 SARS-CoV-2-specific T cell response observed in children suggests that other compartments of the immune
197 system, such as the innate immune response, contribute to faster clearing of the infection, as demonstrated
198 by others [24-26]. The higher T cell responses in infected adults could largely be explained by higher T cell
199 responses found in moderate cases, although adults with mild complaints also tended to have slightly higher
200 responses than infected children. This is in agreement with findings from other studies showing higher
201 frequencies of SARS-CoV-2-specific T cells in severe patients compared to mildly symptomatic patients [8, 15].

202 In contrast, critically ill patients have been reported to exhibit qualitatively impaired S-SARS-CoV-2-specific
203 CD4⁺ T cell responses, indicating that a good CD4⁺ T cell response may protect against serious disease [15]. It
204 has been demonstrated that SARS-CoV-2-specific T cell responses can be retained >8 months following
205 infection regardless of disease severity [7, 16, 27, 28]. In line with these results, we also do find memory
206 responses, which could be indicative of sustained T cell immunity after mild SARS-CoV-2 infection. In
207 agreement with our IFN- γ ELISPOT data, significantly lower frequencies of SARS-CoV-2-specific activated
208 (CD25⁺/CD137⁺)/CD4⁺ T cells were observed in infected children compared to infected adults. Recently, Cohen

et al. (2021) also described that acute and memory CD4⁺ T cells in children were significantly lower than in adults, while polyfunctional cytokine production by T cells was comparable [20]. In accordance with Cohen et al. [20], we found that the SARS-CoV-2 activated T cells mainly belonged to the CD4⁺ effector memory subset (T_{EM}: CD45RO⁺/CCR7⁻). Data on the SARS-CoV-2-specific IFN- γ ⁺ T cell response and CD4⁺ T cell activation correlated, suggesting that IFN- γ was produced by antigen-specific CD4⁺ T cells. Apart from IFN- γ , SARS-CoV-2-specific T cells produced IL-2, suggesting a Th1 phenotype of the CD4⁺ T_{EM}.

In contrast, very low frequencies of activated (CD25⁺/CD137⁺) CD8⁺ T cells were detected after SARS-CoV-2-specific stimulation. An explanation for this may be that CD8⁺ T cells have migrated to the local sites of infection to attack virus-infected cells or might be a result of the antigenic stimulation used in our study. Smaller peptides (9 to 10-mers instead of 15-mers) or live SARS-CoV-2 may be more suitable to measure CD8⁺ T cell responses. Sekine et al. also observed proportionately larger SARS-CoV-2-specific CD4⁺ T cell responses than CD8⁺ T cell responses to different sets of overlapping peptides in the convalescent phase of both mild and severe COVID-19 cases, although in that study also IFN- γ ⁺ CD8⁺ T cell responses were detected [8].

Pre-existing cross-reactive T cell immunity generated by common cold human coronaviruses (HCoV) has been suggested to affect clinical outcomes of SARS-CoV-2 infection. T cell lines from unexposed healthy donors specific for S-HCoV-229E and -OC43 were cross-reactive to S-SARS-CoV-2 [29]. Based on these findings, the authors suggested that children may have higher HCoV prevalence due to more frequent social contacts, explaining their lower risk for severe COVID-19 [29]. In the present study, we did, however, not find a significant difference in the low frequencies of S-HCoV-OC43-reactive IFN- γ ⁺ T cells between unexposed children and unexposed adults. In another study with mild COVID-19 adult patients, also low T cell frequencies recognizing S-HCoV-229E/S-HCoV-OC43 peptide pools were found [15]. It cannot be excluded that pre-existing cross-reactive immunity to other conserved parts of SARS-CoV-2 played a role, or that pre-existing immunity to other HCoV played a role. We, however, found no evidence that pre-existing S-HCoV-OC43-reactive T cells boosted upon SARS-CoV-2 infection could explain the mild course of infection.

We found positive correlations between SARS-CoV-2-specific IFN- γ ⁺ T cell frequency and serum-IgG, -IgM, and -IgA antibody concentrations to S1-SARS-CoV-2 in both children and adults. Although, it should be taken into

235 account that the antibody concentrations of considerable numbers of children were below the threshold for
 236 seropositivity [10]. Other studies have also shown positive correlations between S-SARS-CoV-2-specific IgG
 237 antibodies and T cell responses [6, 30, 31].

238 Limited data is available on the immune response to SARS-CoV-2 in children. Here, we show significantly
 239 higher frequencies of SARS-CoV-2-specific T cells in infected children compared to unexposed age-matched
 240 controls. Frequencies of SARS-CoV-2 reactive T cells were lower in infected children whom almost all had
 241 mild/asymptomatic infection compared to infected adults with mild to moderate COVID-19. Predominantly
 242 CD4⁺ T cells, and not CD8⁺ T cells, were activated upon stimulation with SARS-CoV-2 antigens. SARS-CoV-2-
 243 specific T cell responses were more prominent in infected adults with moderate symptoms than with mild
 244 infection. Importantly, our data indicate that an effector memory T cell response is developed after
 245 experiencing mild SARS-CoV-2 infection. It is tempting to speculate that such responses may contribute at least
 246 partially to protection against re-infection and might limit the spread of the virus. A follow-up study is planned
 247 to evaluate the long-term T cell response.

248

249

250 **Funding**

251 This work was supported by the Dutch Ministry of Health, Welfare and Sport.

252

253 **Acknowledgments**

254 We are grateful to the members of the Dutch FFX-COVID-19 research group of the Centre for Infectious
 255 Disease Control, National Institute for Public Health and the Environment, the Netherlands, that includes
 256 Arianne van Gageldonk-Lafeber, Wim van der Hoek, Susan van den Hof, Chantal Reusken and Inge Roof for
 257 their contribution to the design and the conduct of the SARS-CoV-2-related clinical study. We thank the Public
 258 Health Service Utrecht for assistance in the recruitment of households. We thank Anneke Westerhof, Anne-
 259 Marie van den Brandt, Aniek Backx, Bas van der Veer, Elma Smeets -Roelofs, Elsa Porter, Elske Bijvank, Fion
 260 Brouwer, Françoise van Heiningen, Gabriel Goderski, Gert-Jan Godeke, Harry van Dijken, Helma Lith, Hinke ten
 261 Hulscher, Ilse Akkerman, Ilse Schinkel, Jeroen Hoeboer, Johan Reimerink, Jolanda Kool, Josien Lanfermeijer,
 262 Joyce Greeber, Kim Freriks, Kina Helm, Lidian Izeboud, Lisa Wijsman, Liza Tymchenko, Martijn Vos, Margriet
 263 Bisschoff, Marieke Hoogerwerf, Marit de Lange, Marit Middeldorp, Marjan Bogaard, Marjan Kuijer, Nening
 264 Nanlohy, Olga de Bruin, Rob van Binnendijk, Rogier Bodewes, Ronald Jacobi, Ruben Wiegman, Sakinie
 265 Misiedjan, Saskia de Goede, Sharon van den Brink, Sophie van Tol, Teun Guichelaar, Titia Kortbeek, and
 266 Yolanda van Weert for support during the stages of this study, household visits, processing samples and
 267 laboratory analyses.

268

269 **Conflict of interest**

270 None of the authors have an association that poses a conflict of interest.

References

1. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* **2020**; 584(7821): 463-9.
2. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* **2020**; 369(6508): eabc8511.
3. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* **2020**; 27(6): 992-1000 e3.
4. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci Immunol* **2020**; 5(49).
5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* **2020**; 323(13): 1239-42.
6. Reynolds CJ, Swadling L, Gibbons JM, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. *Science Immunology* **2020**; 5(54): eabf3698.
7. Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell* **2021**; 184(1): 169-83 e17.
8. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell* **2020**; 183(1): 158-68 e14.
9. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. *Nat Rev Immunol* **2020**; 20(10): 581-2.
10. den Hartog G, Vos ERA, van den Hoogen LL, et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. *Clin Infect Dis* **2021**.
11. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* **2020**; 5(12): 1598-607.

296 12. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and
297 SARS, and uninfected controls. *Nature* **2020**; 584(7821): 457-62.

298 13. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in
299 protection. *Sci Immunol* **2020**; 5(49).

300 14. Gallais F, Velay A, Nazon C, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular
301 Immune Response without Seroconversion, France. *Emerg Infect Dis* **2021**; 27(1).

302 15. Oja AE, Saris A, Ghandour CA, et al. Divergent SARS-CoV-2-specific T- and B-cell responses in severe
303 but not mild COVID-19 patients. *Eur J Immunol* **2020**; 50(12): 1998-2012.

304 16. Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6
305 months following primary infection. *Nat Immunol* **2021**; 22(5): 620-6.

306 17. Jia R, Wang X, Liu P, et al. Mild Cytokine Elevation, Moderate CD4(+) T Cell Response and Abundant
307 Antibody Production in Children with COVID-19. *Virol Sin* **2020**; 35(6): 734-43.

308 18. Moratto D, Giacomelli M, Chiarini M, et al. Immune response in children with COVID-19 is
309 characterized by lower levels of T-cell activation than infected adults. *Eur J Immunol* **2020**; 50(9): 1412-
310 4.

311 19. Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of parents
312 with symptomatic COVID-19. *Nat Commun* **2020**; 11(1): 5703.

313 20. Cohen CA, Li APY, Hachim A, et al. SARS-CoV-2 specific T cell responses are lower in children and
314 increase with age and time after infection. *Nat Commun* **2021**; 12(1): 4678.

315 21. Reukers DFM, van Boven M, Meijer A, et al. High infection secondary attack rates of SARS-CoV-2 in
316 Dutch households revealed by dense sampling. *Clin Infect Dis* **2021**.

317 22. Rosendahl Huber SK, Hendriks M, Jacobi RHJ, et al. Immunogenicity of Influenza Vaccines: Evidence for
318 Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity. *Front Immunol* **2018**;
319 9: 3103.

- den Hartog G, Schepp RM, Kuijer M, et al. SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. *J Infect Dis* **2020**; 222(9): 1452-61.
- Pierce CA, Sy S, Galen B, et al. Natural mucosal barriers and COVID-19 in children. *JCI Insight* **2021**; 6(9).
- Neeland MR, Bannister S, Clifford V, et al. Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. *Nat Commun* **2021**; 12(1): 1084.
- Loske J, Rohmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol* **2021**.
- Sherina N, Piralla A, Du L, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. *Med (N Y)* **2021**; 2(3): 281-95 e4.
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **2021**.
- Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **2020**; 587(7833): 270-4.
- Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol* **2020**; 5(48).
- Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **2020**; 181(7): 1489-501 e15.

Table 1. Demographic and clinical characteristics of unexposed participants and the cohort of PCR confirmed SARS-CoV-2 infection

Characteristics	Adults total n = 27	Adults mild n = 16	Adults moderate n = 11	Unexposed adults n = 12	Children n = 24	Unexposed children n = 13
Median age (range) – years	44 (18 – 87)	45 (18 – 87)	44 (18 – 54)	38 (20 – 51)	12 (2 – 16)	12 (2 – 16)
Sex – number (%)						
Male	14 (51.9)	9 (56.3)	5 (45.5)	6 (50.0)	11 (45.8)	5 (38.5)
Female	13 (48.1)	7 (43.7)	6 (54.5)	6 (50.0)	13 (54.2)	8 (61.5)
Serology positivity (above cut-off) to Spike-S1 – number (%)						
IgM	27 (100.0)	16 (100.0)	11 (100.0)	N/A	20 (83.3)	N/A
IgG	26 (96.3)	15 (93.7)	11 (100.0)		19 (79.2)	
IgA	24 (88.9)	13 (81.2)	11 (100.0)		18 (75.0)	
T cell response positivity (≥ 5 spots) to Spike – number (%)						
IFN-γ ELISPOT	27 (100.0)	16 (100.0)	11 (100.0)	1 (8.3)	20 (83.3)	0 (0.0)
Disease severity ^A – number (%)						
Asymptomatic ^B	0 (0.0)	0 (0.0)	0 (0.0)	N/A	3 (12.5)	N/A
Mild	16 (59.3)	16 (100.0)	0 (0.0)		19 (79.2)	
Moderate/Hospitalized	11 (40.7)	0 (0.0)	11 (100.0)		2 (8.3)	
Sign and symptoms – number (%)						
Any sign or symptom	27 (100)	16 (100.0)	11 (100.0)	N/A	21 (87.5)	N/A
Fever	14 (51.9)	8 (50.0)	6 (54.5)		6 (25.0)	
Cough	20 (74.1)	9 (56.3)	11 (100.0)		11 (45.8)	
Chills	15 (55.6)	8 (50.0)	7 (63.6)		2 (8.3)	
Sore throat	14 (51.9)	9 (56.3)	5 (45.5)		3 (12.5)	
Runny nose	18 (66.7)	11 (68.8)	7 (63.6)		15 (62.5)	
Phlegm	12 (44.4)	7 (43.7)	5 (45.5)		2 (8.3)	
Headache	20 (74.1)	13 (81.2)	7 (63.6)		7 (29.2)	
Myalgia	20 (74.1)	12 (75.0)	8 (72.7)		1 (4.2)	
Fatigue	24 (88.9)	13 (81.2)	11 (100.0)		6 (25.0)	
Shortness of breath	9 (33.3)	0 (0.0)	9 (81.8)		2 (8.3)	
Loss of taste or smell	11 (40.7)	5 (31.2)	6 (54.5)		3 (12.5)	
Diarrhea	11 (40.7)	6 (37.5)	5 (45.5)		2 (8.3)	
Medical care						
General practitioner	5 (18.5)	2 (12.5)	3 (27.3)	N/A	2 (8.3)	N/A
Hospitalization	7 (25.9)	0 (0.0)	7 (63.6)		0 (0.0)	
Comorbidities – number (%)						
Total	14 (51.9)	7 (43.7)	7 (63.6)	0 (0.0)	7 (29.2)	6 (46.2)
Cardiovascular disease	2 (7.4)	1 (6.3)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)
Lung disease	4 (14.8)	0 (0.0)	4 (36.4)	0 (0.0)	4 (16.7)	3 (23.1)
Proteinuria	1 (3.7)	0 (0.0)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)
Lupus	1 (3.7)	1 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Osteoporosis	1 (3.7)	1 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Allergies	5 (18.5)	4 (25.0)	1 (9.1)	0 (0.0)	6 (25.0)	5 (38.5)

^ADisease severity was classified as asymptomatic (absence of symptoms), mild (at least one symptom but absence of shortness of breath), moderate (presence of shortness of breath with or without other symptoms, including hospitalized cases). None of the hospitalized patients were admitted to an intensive care unit, thus not considered severe cases. ^BThree children were remained asymptomatic during the study but tested PCR positive. n, number of subjects in specific group; Spike-S1, SARS-CoV-2 Spike S1 protein; Spike, overlapping peptides of SARS-CoV-2 spike protein; N/A, not applicable

Figure legends

Figure 1. SARS-CoV-2-specific IFN- γ ⁺ T cell response in infected children and infected adults (mild and moderate cases) versus unexposed healthy controls over time after infection

Dot plots summarizing the frequencies of IFN- γ -producing cells responding to SARS-CoV-2 and HCoV-OC43 antigens for (A-D) children (left panel), adults (right panel), over time after infection, and compared to unexposed adults/children (ELISPOT assay). Frequencies of IFN- γ -producing cells responding to (A) set of overlapping of peptides of SARS-CoV-2 spike protein, (B) set of overlapping peptides of SARS-CoV-2 nucleocapsid protein, (C) inactivated SARS-CoV-2, and (D) set of overlapping peptides of HCoV-OC43 spike protein. (E) Comparison of IFN- γ -producing cells derived from infected children, mild symptomatic SARS-CoV-2-infected adults versus adult COVID-19 patients with moderate symptoms at T1, (F) at T2, and (G) mild symptomatic SARS-CoV-2-infected adults versus adult COVID-19 patients with moderate symptoms at T3. Each dot represents one subject. Bars indicate the median of spot-forming units per 200,000 PBMCs. SFU, spot-forming unit. (A-D) P values related to comparisons with the unexposed controls are listed at the top of the graph, above the corresponding group for comparison. For unpaired comparisons, Mann-Whitney U test (two-group comparisons) (mild adults versus moderate adults) or Kruskal-Wallis rank-sum test with Dunn's posthoc test for multiple comparisons were used (children versus mild adults versus moderate adults; unexposed versus infected children or adults at T1 versus T2 versus T3). Differences between paired data were compared using the Wilcoxon signed-rank test (for comparison of two paired groups) (infected children at T1 versus T2) or the Friedman test with Dunn's multiple comparison tests (infected adults at T1 versus T2 versus T3). Statistically significant comparisons are indicated, with P values < 0.05 considered significant. T1, first timepoint of sampling for adults median 12.5 days and children median 8 days post-symptom onset; T2, 10-14 days after T1; T3, 4-6 weeks after T1.

Figure 2. Frequencies of activated CD4⁺ T cells of infected children and infected adults (mild and moderate cases) versus unexposed healthy controls over time after infection

Dot plots summarizing the percentages of CD25⁺/CD137⁺ activated CD4⁺ T cells responding to SARS-CoV-2 and HCoV-OC43 antigens for (A-D) children (left panel), adults (right panel), over time after infection, and compared to unexposed adults/children. Percentages of CD25⁺/CD137⁺ activated CD4⁺ T cells responding to (A) set of overlapping peptides of SARS-CoV-2 spike protein, (B) set of overlapping peptides of SARS-CoV-2 nucleocapsid, (C) inactivated SARS-CoV-2, and (D) set of overlapping peptides of HCoV-OC43 spike protein. (E) Comparison of IFN- γ -producing cells derived from infected children, mild symptomatic SARS-CoV-2-infected adults versus adult COVID-19 patients with moderate symptoms at T1, (F) at T2, and (G) mild symptomatic SARS-CoV-2-infected adults versus adult COVID-19 patients with moderate symptoms at T3. (H) Immunophenotyping at the single-cell level showed the different memory subsets within the SARS-CoV-2-specific activated CD4⁺ T cells from infected adults.

Each dot represents one subject. Bars indicate the median percentage of total CD4⁺ T cells. (A-D) P values related to comparisons with the unexposed controls are listed at the top of the graph, above the corresponding group for comparison. For unpaired comparisons, Mann-Whitney U test (two-group comparisons) (mild adults versus moderate adults) or Kruskal-Wallis rank-sum test with Dunn's posthoc test for multiple comparisons were used (children versus mild adults versus moderate adults; unexposed versus infected children or adults at T1 versus T2 versus T3). Differences between paired data were compared using the Wilcoxon signed-rank test (for comparison of two paired groups) (infected children at T1 versus T2) or the Friedman test with Dunn's multiple comparison tests (infected adults at T1 versus T2 versus T3). Statistically significant comparisons are indicated, with P values < 0.05 considered significant. T1, first timepoint of sampling for adults median 12.5 days and children median 8 days post-symptom onset; T2, 10-14 days after T1; T3, 4-6 weeks after T1.

Figure 3. Correlation between IFN- γ ⁺ T cell frequency and activated CD4⁺ T cells

Spearman correlation between frequency of IFN- γ ⁺ responder cells and percentages of CD25⁺/CD137⁺ activated CD4⁺ T cells of (A) children and (B) adults responding to a set of overlapping peptides of SARS-CoV-2 spike protein (left panel), or a set of overlapping peptides of SARS-CoV-2 nucleocapsid protein (middle panel) or inactivated SARS-CoV-2 (right panel) at different time points after infection. (C) Heatmaps summarizing the pairwise correlations. Each dot represents one subject. Correlation coefficients (r_s) were determined with Spearman's rank correlation. P values < 0.05 were considered significant.

T1, first timepoint of sampling for adults median 12.5 days and children median 8 days post-symptom onset; T2, 10-14 days after T1; T3, 4-6 weeks after T1.

Figure 4. Cytokine release in infected children and mild versus moderate symptomatic adults over time after infection

Cell-free culture supernatants were harvested from IFN- γ ELISPOT plates and the release of the following cytokines was measured in T1 samples: IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-22. Dot plots show the concentration of cytokines (pg/ml) after stimulation of PBMCs with a set of overlapping peptides of SARS-CoV-2 spike protein. Infected children and unexposed children versus infected adults with mild or moderate disease and unexposed adults are depicted. Minimum detection threshold (MDT) concentrations for each cytokine, as calculated by the manufacture and mentioned in Supplemental Methods, are indicated with horizontal dotted lines.

Each dot represents one subject. Bars indicate the median cytokine concentration (pg/ml). For two-group comparisons (infected children versus unexposed children), Mann-Whitney U test was used. Kruskal-Wallis rank-sum test with Dunn's posthoc test for multiple comparisons was used (all adults vs mild adults versus moderate adults versus unexposed adults; all adults vs mild adults versus moderate adults versus infected children). P-values $\leq$ 0.05 are presented.

421 **Figure 5. Correlation between IFN- γ ⁺ T cell frequency and antibody concentrations to S-SARS-CoV-2**

422 Spearman correlation between frequency of IFN- γ ⁺ responder cells and concentrations of Spike-SARS-CoV-2

423 IgM, IgG, or IgA antibodies at different time points after infection in (A) children and (B) adults. (C) Heatmaps

424 summarizing the pairwise correlations. Cut-off values for seroprevalence are 1.20, 1.04, and 0.50 AU/ml for

425 Spike-SARS-CoV-2-specific IgM, IgG, and IgA, respectively, and are indicated with vertical dotted lines. Each dot

426 represents one subject. Correlation coefficients (r_s) were determined with Spearman's rank correlation. P

427 values < 0.05 were considered significant.

428 T1, first timepoint of sampling for adults median 12.5 days and children median 8 days post-symptom onset;

429 T2, 10-14 days after T1; T3, 4-6 weeks after T1.

430

Figure 1

Figure 2

Figure 3

Figure 4

A

Figure 5